Stereotactic body radiotherapy: An effective local treatment modality for hepatocellular carcinoma

Jonathan H. Klein, Renee Korol, Simon S. Lo, William Chu, Michael Lock, Jennifer A. Dorth, Rodney J. Ellis, Nina A. Mayr, Zhibin Huang, Hans T. Chung

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Although liver-directed therapies such as surgery or ablation can cure hepatocellular carcinoma, few patients are eligible due to advanced disease or medical comorbidities. In advanced disease, systemic therapies have yielded only incremental survival benefits. Historically, radiotherapy for liver cancer was dismissed due to concerns over unacceptable toxicities from even moderate doses. Although implementation requires more resources than standard radiotherapy, stereotactic body radiotherapy can deliver reproducible, highly conformal ablative radiotherapy to tumors while minimizing doses to nearby critical structures. Trials of stereotactic body radiotherapy for hepatocellular carcinoma have demonstrated promising local control and survival results with low levels of toxicity in Child-Pugh class A patients. We review the published literature and make recommendations for the future of this emerging modality.

Original languageEnglish (US)
Pages (from-to)2227-2241
Number of pages15
JournalFuture Oncology
Volume10
Issue number14
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Radiosurgery
Hepatocellular Carcinoma
Radiotherapy
Conformal Radiotherapy
Survival
Liver Neoplasms
Comorbidity
Liver
Therapeutics
Neoplasms

Keywords

  • hepatocellular carcinoma
  • liver neoplasms
  • radiotherapy
  • stereotactic body radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Stereotactic body radiotherapy : An effective local treatment modality for hepatocellular carcinoma. / Klein, Jonathan H.; Korol, Renee; Lo, Simon S.; Chu, William; Lock, Michael; Dorth, Jennifer A.; Ellis, Rodney J.; Mayr, Nina A.; Huang, Zhibin; Chung, Hans T.

In: Future Oncology, Vol. 10, No. 14, 01.01.2014, p. 2227-2241.

Research output: Contribution to journalArticle

Klein, JH, Korol, R, Lo, SS, Chu, W, Lock, M, Dorth, JA, Ellis, RJ, Mayr, NA, Huang, Z & Chung, HT 2014, 'Stereotactic body radiotherapy: An effective local treatment modality for hepatocellular carcinoma', Future Oncology, vol. 10, no. 14, pp. 2227-2241. https://doi.org/10.2217/fon.14.167
Klein, Jonathan H. ; Korol, Renee ; Lo, Simon S. ; Chu, William ; Lock, Michael ; Dorth, Jennifer A. ; Ellis, Rodney J. ; Mayr, Nina A. ; Huang, Zhibin ; Chung, Hans T. / Stereotactic body radiotherapy : An effective local treatment modality for hepatocellular carcinoma. In: Future Oncology. 2014 ; Vol. 10, No. 14. pp. 2227-2241.
@article{190ff2d27d214fe58b639793329cbfc5,
title = "Stereotactic body radiotherapy: An effective local treatment modality for hepatocellular carcinoma",
abstract = "Although liver-directed therapies such as surgery or ablation can cure hepatocellular carcinoma, few patients are eligible due to advanced disease or medical comorbidities. In advanced disease, systemic therapies have yielded only incremental survival benefits. Historically, radiotherapy for liver cancer was dismissed due to concerns over unacceptable toxicities from even moderate doses. Although implementation requires more resources than standard radiotherapy, stereotactic body radiotherapy can deliver reproducible, highly conformal ablative radiotherapy to tumors while minimizing doses to nearby critical structures. Trials of stereotactic body radiotherapy for hepatocellular carcinoma have demonstrated promising local control and survival results with low levels of toxicity in Child-Pugh class A patients. We review the published literature and make recommendations for the future of this emerging modality.",
keywords = "hepatocellular carcinoma, liver neoplasms, radiotherapy, stereotactic body radiotherapy",
author = "Klein, {Jonathan H.} and Renee Korol and Lo, {Simon S.} and William Chu and Michael Lock and Dorth, {Jennifer A.} and Ellis, {Rodney J.} and Mayr, {Nina A.} and Zhibin Huang and Chung, {Hans T.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2217/fon.14.167",
language = "English (US)",
volume = "10",
pages = "2227--2241",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "14",

}

TY - JOUR

T1 - Stereotactic body radiotherapy

T2 - An effective local treatment modality for hepatocellular carcinoma

AU - Klein, Jonathan H.

AU - Korol, Renee

AU - Lo, Simon S.

AU - Chu, William

AU - Lock, Michael

AU - Dorth, Jennifer A.

AU - Ellis, Rodney J.

AU - Mayr, Nina A.

AU - Huang, Zhibin

AU - Chung, Hans T.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Although liver-directed therapies such as surgery or ablation can cure hepatocellular carcinoma, few patients are eligible due to advanced disease or medical comorbidities. In advanced disease, systemic therapies have yielded only incremental survival benefits. Historically, radiotherapy for liver cancer was dismissed due to concerns over unacceptable toxicities from even moderate doses. Although implementation requires more resources than standard radiotherapy, stereotactic body radiotherapy can deliver reproducible, highly conformal ablative radiotherapy to tumors while minimizing doses to nearby critical structures. Trials of stereotactic body radiotherapy for hepatocellular carcinoma have demonstrated promising local control and survival results with low levels of toxicity in Child-Pugh class A patients. We review the published literature and make recommendations for the future of this emerging modality.

AB - Although liver-directed therapies such as surgery or ablation can cure hepatocellular carcinoma, few patients are eligible due to advanced disease or medical comorbidities. In advanced disease, systemic therapies have yielded only incremental survival benefits. Historically, radiotherapy for liver cancer was dismissed due to concerns over unacceptable toxicities from even moderate doses. Although implementation requires more resources than standard radiotherapy, stereotactic body radiotherapy can deliver reproducible, highly conformal ablative radiotherapy to tumors while minimizing doses to nearby critical structures. Trials of stereotactic body radiotherapy for hepatocellular carcinoma have demonstrated promising local control and survival results with low levels of toxicity in Child-Pugh class A patients. We review the published literature and make recommendations for the future of this emerging modality.

KW - hepatocellular carcinoma

KW - liver neoplasms

KW - radiotherapy

KW - stereotactic body radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84916602426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916602426&partnerID=8YFLogxK

U2 - 10.2217/fon.14.167

DO - 10.2217/fon.14.167

M3 - Article

C2 - 25471036

AN - SCOPUS:84916602426

VL - 10

SP - 2227

EP - 2241

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 14

ER -